[P-16] Characterisation of genomic alteration of FGFR3 by integrating analysis of the Cancer Genome Atlas
Mutations and fusions of the fibroblast growth factor receptor (FGFR) gene family occur in various cancer types. Recently erdafitinib has been approved by the FDA for the treatment of FGFR3-altered urothelial cancer. We performed an integrated analysis of the TCGA-pancancer atlas including 32 cancer types (n = 10,953) to reveal the novel alteration of FGFR3....
Category :
Brief communications
[P-12] Integrating analysis of the expression of IDO1 and TDO2 in bladder cancer
Several lines of evidence have been focused on the roles of tryptophan metabolism genes like indoleamine 2,3-dioxygenase 1 (IDO1) and tryptophan 2,3-dioxygenase (TDO2) in bladder cancer progression. However, the alternative way of targeting in cancer immunotherapy has been not yet investigated in bladder cancer....
Category :
Brief communications
Page :
1